Phase 3 Clinical Trials With Primary Completion Dates in December 2022
This is a list of Phase 3 trials with primary completion dates in December 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | 2022-12-01 | Phase 3 | NCT04707768 | Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects |
| AMRX | Amneal Pharmaceuticals, Inc. | 2022-12-01 | Phase 3 | NCT05401357 | Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes. |
| ARQT | Arcutis Biotherapeutics, Inc. | 2022-12-01 | Phase 3 | NCT04845620 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) |
| AXSM | Axsome Therapeutics, Inc. | 2022-12-01 | Phase 3 | NCT04797715 | Assessing Clinical Outcomes in Alzheimer's Disease Agitation |
| BIVI | BioVie Inc. | 2022-12-01 | Phase 3 | NCT04669028 | A Phase 3 Study of NE3107 in Probable Alzheimer's Disease |
| BVNRY | Bavarian Nordic A/S | 2022-12-01 | Phase 3 | NCT05329220 | ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 |
| CORT | Corcept Therapeutics Incorporated | 2022-12-01 | Phase 3 | NCT04308590 | Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas |
| EIGR | Eiger BioPharmaceuticals, Inc. | 2022-12-01 | Phase 3 | NCT03719313 | Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a |
| ESPR | Esperion Therapeutics, Inc. | 2022-12-01 | Phase 3 | NCT02993406 | Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo |
| IMGN | ImmunoGen, Inc. | 2022-12-01 | Phase 3 | NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression |
| ITCI | Intra-Cellular Therapies, Inc. | 2022-12-01 | Phase 3 | NCT04285515 | Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder |
| IVBXF | Innovent Biologics, Inc. | 2022-12-01 | Phase 3 | NCT04277663 | The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery |
| IVBXF | Innovent Biologics, Inc. | 2022-12-01 | Phase 3 | NCT03607539 | Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC |
| IVBXF | Innovent Biologics, Inc. | 2022-12-01 | Phase 3 | NCT03150875 | A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC |
| MDGL | Madrigal Pharmaceuticals, Inc. | 2022-12-01 | Phase 3 | NCT03900429 | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis |
| MEDP | Medpace Holdings, Inc. | 2022-12-01 | Phase 3 | NCT03464019 | Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)] |
| MIST | Milestone Pharmaceuticals Inc. | 2022-12-01 | Phase 3 | NCT04072835 | Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303 |
| MIST | Milestone Pharmaceuticals Inc. | 2022-12-01 | Phase 3 | NCT03464019 | Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)] |
| MMSI | Merit Medical Systems, Inc. | 2022-12-01 | Phase 3 | NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant |
| NAMS | NewAmsterdam Pharma Company N.V. | 2022-12-01 | Phase 3 | NCT05142722 | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies |
| NEPH | Nephros, Inc. | 2022-12-01 | Phase 3 | NCT04466618 | Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes |
| NEPH | Nephros, Inc. | 2022-12-01 | Phase 3 | NCT04459338 | A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion |
| OPTN | OptiNose, Inc. | 2022-12-01 | Phase 3 | NCT03747458 | OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps |
| OTLK | Outlook Therapeutics, Inc. | 2022-12-01 | Phase 3 | NCT05112861 | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders |
| RLMD | Relmada Therapeutics, Inc. | 2022-12-01 | Phase 3 | NCT04855747 | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2022-12-01 | Phase 3 | NCT01478542 | OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine |
| STSA | Satsuma Pharmaceuticals, Inc. | 2022-12-01 | Phase 3 | NCT04406649 | A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine |
| URGN | UroGen Pharma Ltd. | 2022-12-01 | Phase 3 | NCT05136898 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) |
| VBLT | Vascular Biogenics Ltd. | 2022-12-01 | Phase 3 | NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) |
| VNDA | Vanda Pharmaceuticals Inc. | 2022-12-01 | Phase 3 | NCT04652882 | Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) |
| ZLDPF | Zealand Pharma A/S | 2022-12-01 | Phase 3 | NCT04991311 | The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome |
| ZLDPF | Zealand Pharma A/S | 2022-12-01 | Phase 3 | NCT03941236 | Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism |